That is a genuine concern for me @TheJuggernaut. Investment in...

That is a genuine concern for me @TheJuggernaut. Investment in any biotech/Pharma is one of the first things to look at for trial drugs & watertight IP. Big Pharma is very cut throat. You read sites like Fierce Pharma & Fierce Biotech, every few articles they are suing each other over IP or Biosimilars.

Although an article I posted a while ago when discussing this topic with @Bilson, it appears that higher life forms (ie plants) cannot be patented or their derivatives, unless they are GMO’s or synthetics. MXC has seed to Pharma production, that in itself is encouraging. I don’t believe any MC company can just slap together a formulation that will be most effective for epilepsy. Years of research have gone into this & that cannot be discounted.

For @win8 it’s the TGA in Australia that approve drugs for investigational purposes & Special Access Scheme (CannEpil has approval). FDA is USA. I have posted this site b4 on another thread, but will do so again for your own research purposes & anyone else this is helpful to & remember to do a modified search for all, as it will go to default of “now recruiting”. You can check on ethics approval, whatever. Be one step ahead of the game

https://www.australianclinicaltrials.gov.au/

For the USA & other countries who register there (204 countries):

https://clinicaltrials.gov/

To the best of my knowledge, MXC have a research relationship with RMIT & now also Notre Dame WA for Dementia trial. Plus teaching hospital in Melbourne where Prof Wendyl is based. Note: CannEpil is approved for Special Access Scheme scripts from a Specialist Neurologist, there was no mention or necessity to be on a clinical trial for access, unlike some other investigational drugs. I hope that helps GLTA